Therefore, in this current study, we present the latest evidence about glucagon-like peptide-1 receptor agonists (GLP-1RA) and dipeptydilpeptidase-4 inhibitors (DPP-4i), which are a relatively newer class of antihyperglycemic agents on hypertension in the diabetic milieu. The gene discussed is GLP1R; the disease is hypertensive disorder.